Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190500 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2EPHX1HTT | |
| SCHEMBL9349040 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2EPHX1HTT | |
| SCHEMBL8496317 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2EPHX1HTT | |
| SCHEMBL6906654 | 0.98 | ALDH1A1 (0.33) | ALDH1A1TDP1USP2EPHX1HTT | |
| SCHEMBL9160306 | 0.98 | ALDH1A1 (0.33) | ALDH1A1TDP1USP2EPHX1HTT | |
| SCHEMBL17844871 | 0.87 | MEN1 (0.31) | ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL27160684 | 0.85 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL8075279 | 0.84 | MAPT (0.34) | — | |
| SCHEMBL28900411 | 0.83 | ALDH1A1 (0.37) | ALDH1A1TDP1EPHX1SPHK2SPHK1 | |
| SCHEMBL29087903 | 0.83 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226052-A1 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | HELSINGIN YLIOPISTO (FI) | 2024-07-11 | — | — | US | disclosed |
| EP-4329730-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | Helsingin Yliopisto (FI) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229441-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | HELSINGIN YLIOPISTO (FI) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226052-A1 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | LIPA, MGLL, CETP | ALDH1A1 1768/4885TDP1 2992/4885USP2 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.